July 31, 2017, 6:20 a.m.
Extracted Keywords:

ellie donnelly july dublin am synexa life synexa life sciences

Stream Keywords: life sciences,donnelly ellie,sciences synexa,life synexa,dublin synexa,dublin life,dublin sciences,donnelly july,ellie july,am synexa,am life

Ellie Donnelly

July 31 2017 7:17 AM

Synexa Life Sciences has opened of its international headquarters in Dublin.

The biomarker services company said that the centre will be home to its global business development activities and a new bioinformatics lab.
The company expects to create up to 30 highly skilled jobs over the next five years at the headquarters.
Welcoming the decision, the Tánaiste and Minister for Business, Enterprise and Innovation, Frances Fitzgerald T.D. described it as a "great win for Ireland, bringing high quality jobs involving cutting-edge science and research for the biotechnology and pharmaceutical industry and will help drive the development of new products by the industry".
Read more: Biotech company Ipsen Manufacturing Ireland Limited ramps up recruitment
The company, which provides biomarker services to the global biotech and pharmaceutical industry, operates operates biomarker research laboratories in Berlin, London and Cape Town, where the company was founded in 2003 by Irishman Paul O’Riordan and scientists Dr. Justin Devine and Prof. Patrick Bouic.
"Ireland has a well-deserved reputation as one of the world’s most open and business-friendly environments, making the decision to locate our international HQ here very straightforward," Mr O’Riordan said, CEO of Synexa, said.
Founded in 2003 as an early pioneer in the new field of biomarker services, Synexa has grown to offer a comprehensive range of analytical and advisory services to global biopharmaceutical companies focused on the identification, development, analysis and interpretation of biomarkers in clinical trials and diagnostic validation programs.
Synexa operates through collaborative, risk-sharing partnerships with clients, aiming to deliver insights that significantly improve the quality of decision-making about a drug through each stage in its development.